| Bioactivity | Trastuzumab MMAE is an anti-human epidermal growth factor receptor 2 (HER2) antibody-drug conjugate (ADC). Trastuzumab MMAE is composed of a humanized anti-HER2 antibody Trastuzumab (HY-P9907), an enzymatically cleavable peptide-linker Valine-citrulline, a tubulin inhibitor Monomethyl auristatin E (MMAE; HY-15162). Trastuzumab MMAE can be used for the research of HER2-positive breast cancer[1]. |
| Appearance | 液体 |
| Transport | Shipping with dry ice. |
| Storage | -80°C, protect from light |
| Reference | [1]. Sajad Yaghoubi, et al. Development and biological assessment of MMAE-trastuzumab antibody-drug conjugates (ADCs). Breast Cancer. 2021 Jan;28(1):216-225. |